Finnish healthtech company CurifyLabs has raised €6.7 million to modernise and automate the manufacturing of compounded medications, making them safer and better suited for the specific, individual needs of patients. This raise brings its funding to €17.6 million.
Compounded medications are critical when commercially available options are unsuitable for a patient due to dosage requirements, potential allergies, dosage form limitations, or drug shortages.
Traditionally, when a patient needs personalised medicine, a doctor writes a prescription and then a pharmacist creates the medication by measuring and mixing the ingredients manually.
The process is slow, costly and crucial for vulnerable patient populations, such as children and cancer patients. In fact, 50 per cent of medicines are not available in doses or formulations approved for children. Just 1 per cent of drugs are personalized through compounding, despite increasing demand.
According to Charlotta Topelius, CEO and Co-founder of CurifyLabs, the current approach to manufacturing compounded medications is outdated, poorly optimised, unnecessarily labor-intensive, prone to human error, and inconsistent in quality:
“Patients with serious conditions may not receive accurate dosages tailored to critical factors like age, weight, and disease severity.
The consequences are real: a 9-month-old baby with cancer, for example, cannot swallow standard tablets and requires a carefully customised formulation. It’s time to work together and modernise how we deliver personalised medicine – because every patient deserves treatment that truly fits their needs.”
Together with pharmacists and based on a decade of research, CurifyLabs has developed a solution to automate the manufacturing of compounded medicine, making the process four times faster and enabling limitless dosing flexibility.
The Compounding System Solution combines carrier agents and active ingredients, as well as hardware and software, and quality control to automate the manufacturing process of tailored medicines.
In the process, CurifyLabs’ high-quality excipient bases, inactive carrier agents, are mixed with active pharmaceutical ingredients from raw materials or crushed tablets. The combination is then dispensed in the desired dosage form, like tablets or liquid, by the Pharma Printer, a desktop-sized compounding robot.
An integrated, cloud-based formulation library guides the pharmacist through a validated compounding process, and quality control tools ensure mass uniformity and remove the risk of human errors.
In addition to the funding round, CurifyLabs has announced the launch of RoboPharma, a €5.6 million EU-funded initiative aiming to create an AI and robotics-driven, decentralised pharmaceutical manufacturing platform.
Funded through the EU4Health program, the project addresses one of the most pressing challenges in European healthcare: the fragility and inflexibility of centralized pharmaceutical supply chains during crises such as pandemics, natural disasters, and global disruptions.
Led by CurifyLabs, the initiative includes six partners and aims to enhance crisis preparedness across Europe at the point of care.
Springvest led the round, which included a €1 million deep tech loan from Business Finland.
According to Aki Soudunsaari, CEO of Springvest Plc,
“We’re seeing rapid growth of the global compounding market which presents an exceptional opportunity for new solutions that have the potential to be ten times better than the existing ways to solve the same challenges.
Simultaneously, CurifyLabs’ entry into the US market, where the vast majority of compounding manufacturing occurs, positions CurifyLabs for substantial growth."
The funding will be used to scale CurifyLabs’ operations and secure high-volume customers in the market.
Lead image: Charlotta Topelius and Niklas Sandler Topelius, co-founders of Curify Labs. Photo: uncredited.
Would you like to write the first comment?
Login to post comments